Asset Details
Do you wish to reserve the book?
Anti-Angiogenic Therapy: Current Challenges and Future Perspectives
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Anti-Angiogenic Therapy: Current Challenges and Future Perspectives
Do you wish to request the book?
Anti-Angiogenic Therapy: Current Challenges and Future Perspectives
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Anti-Angiogenic Therapy: Current Challenges and Future Perspectives
2021
Overview
Anti-angiogenic therapy is an old method to fight cancer that aims to abolish the nutrient and oxygen supply to the tumor cells through the decrease of the vascular network and the avoidance of new blood vessels formation. Most of the anti-angiogenic agents approved for cancer treatment rely on targeting vascular endothelial growth factor (VEGF) actions, as VEGF signaling is considered the main angiogenesis promotor. In addition to the control of angiogenesis, these drugs can potentiate immune therapy as VEGF also exhibits immunosuppressive functions. Despite the mechanistic rational that strongly supports the benefit of drugs to stop cancer progression, they revealed to be insufficient in most cases. We hypothesize that the rehabilitation of old drugs that interfere with mechanisms of angiogenesis related to tumor microenvironment might represent a promising strategy. In this review, we deepened research on the molecular mechanisms underlying anti-angiogenic strategies and their failure and went further into the alternative mechanisms that impact angiogenesis. We concluded that the combinatory targeting of alternative effectors of angiogenic pathways might be a putative solution for anti-angiogenic therapies.
Publisher
MDPI AG,MDPI
Subject
/ Angiogenesis Inhibitors - therapeutic use
/ Animals
/ Drugs
/ Humans
/ Neoplasm Proteins - metabolism
/ Neovascularization, Pathologic - drug therapy
/ Neovascularization, Pathologic - metabolism
/ Neovascularization, Pathologic - pathology
/ Review
/ Tumor Microenvironment - drug effects
/ Tumors
